Exhibit 99.1 Doximity Announces Fiscal 2025 Second Quarter Financial Results Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year SAN FRANCISCO, Calif., November 7, 2024 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescr ...

In the latest trading session, Doximity (DOCS) closed at $41.88, marking a +1.11% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.16%. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.78%. Shares of the medical social networking site have depreciated by 4.93% over the course of the past month, underperforming the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67%. Analysts and investors alike will be keeping a c ...

Doximity (DOCS) closed at $41.42 in the latest trading session, marking a -1.76% move from the prior day. This change lagged the S&P 500's daily loss of 0.92%. At the same time, the Dow lost 0.96%, and the tech-heavy Nasdaq lost 1.6%.The medical social networking site's shares have seen an increase of 1.91% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.68%.The upcoming earnings release of Doximity will be of great interest to investors. The com ...

The Medical Services sector is experiencing significant evolution driven by innovation and digital applications. Growing demand for remote treatment has led to a tremendous upsurge in digital healthcare options over the past few years. Demand for digital healthcare treatment continues to grow in the form of telemedicine-focused online medical and AI-powered technology services backed by the adoption of data and analytics. According to a recent Mordor Intelligence report, the global healthcare analytics mark ...

Company Performance - Doximity (DOCS) closed at $40.88, with a +0.62% change from the previous day's closing price, outperforming the S&P 500's daily loss of 0.19% [1] - The stock has increased by 12.05% over the last month, significantly surpassing the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06% [1] Upcoming Earnings Report - The upcoming EPS for Doximity is projected at $0.26, indicating an 18.18% increase compared to the same quarter of the previous year [2] - Revenue is estimated to be $127.05 million, reflecting an 11.83% increase compared to the same quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at $1.05 per share and revenue at $520.23 million, representing changes of +10.53% and +9.43% respectively from the prior year [3] Analyst Estimates and Stock Performance - Recent changes to analyst estimates for Doximity are important as they reflect evolving short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [3][4] - The Zacks Rank system, which considers estimate changes, provides a rating system that has historically delivered an average annual return of +25% for stocks rated 1 [5] Valuation Metrics - Doximity is currently trading at a Forward P/E ratio of 38.57, which is a premium compared to the industry average Forward P/E of 20.94 [6] - The company has a PEG ratio of 4.29, while the industry average PEG ratio is 1.86 [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 162, placing it in the bottom 36% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estim ...

It's a welcome sight for shareholders who haven't had much to rejoice about lately. What a difference a day can make. Until Aug. 8, shares of Doximity (DOCS 0.69%), a healthcare-focused networking platform, were in the red for the year. However, on Aug. 9, the company's stock skyrocketed by more than 33%, making its year-to-date performance better than that of the broader market. As investors might guess, Doximity's gains had something to do with its latest quarterly report, but even after this jump, shares ...

Morsa Images Pondering the issue of sustainable growth Earlier this month, Doximity, whose shares had been languishing in investor purgatory for most of 2024 reported its results for fiscal Q1 2025. The results were significantly better than had been anticipated with revenues of $127 million compared to the prior forecast of $120 million, and adjusted EBITDA of $66 million compared to a prior forecast of $56 million. Year over year revenue growth was 17% while the adjusted EBITDA rose by 42% and the adjuste ...

Doximity Today DOCS Doximity $36.21 +0.18 (+0.50%) 52-Week Range $19.71 ▼ $37.25 P/E Ratio 50.29 Price Target $31.27 Add to Watchlist Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research. It also provides the latest medical news and research and provides access to various career tools. Do ...

Solskin Introduction & Investment Thesis I last wrote about Doximity (NYSE:DOCS) in April, where I rated the stock a "hold." Although I stated that the stock has a potential upside of at least 29% from its levels back then, I believed that investors would be weary until the management could reignite the growth story. Since then, the stock has climbed 45% as it reported a strong Q1 FY25 earnings report, where revenue and Adjusted EBITDA grew 17% and 41% YoY, respectively, beating estimates. Simultaneously, t ...